Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

With the end of the pandemic, sales of Pfizer’s COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 from $56.7 billion in 2022. In 2025, Pfizer’s revenues from ...

US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year. The drugmaker has set a ...

Awards will also recognise innovation, rising stars from the ECP community, and individuals who have made outstanding ...

Market pessimism has undervalued Pfizer and Rexford, both offering high yields and overlooked growth potential. Learn more on ...

Three supercharged income stocks -- sporting an average yield of 8.63% -- are perfectly positioned to fatten investors' ...

With volatility taking center stage since the beginning of the year, investing in the stock market isn’t as easy as it was.

Biologist Bret Weinstein told Daily Caller News Foundation co-founder Tucker Carlson on Wednesday that he believes the White ...

Strategic investing beats market predictions. Read here for two stocks that offer reliable income, strong business models, ...

Major pharmaceutical companies around the world—and increasingly in South Korea—are turning to artificial intelligence (AI) ...